Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON32871
NL-OMON32871
Completed
Phase 3

The effect of vildagliptin on endothelium-dependent vasodilatation. A double blind, cross-over study in type 2 diabetes mellitus. - Vildagliptin and vasodilatation

niversitair Medisch Centrum Sint Radboud0 sites16 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsendothelial functionEndothelium-dependent vasodilatation1001265310003216

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
endothelial function
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
16
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • •\- type 2 diabetes
  • •\- age 35\-75 years
  • •\- metformin monotherapy or combination therapy
  • •\- HbA1c \< 8\.0%

Exclusion Criteria

  • •\- Renal disease defined as creatinine level \> 130 umol/l
  • •\- Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range
  • •\- Current use of acetylsalicylic acid or vitamine K antagonists
  • •\- History of smoking within the past year
  • •\- History of or current abuse of drugs or alcohol
  • •\- History of heartfailure (NYHA class III or IV)
  • •\- Abnormalities on ECG that might interfere with current study protocol
  • •\- Pregnancy or breastfeeding
  • •\- Inability to understand the nature and extent of the trial and procedures required
  • •\- Presence of any medical condition that might interfere with the current study protocol

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
The effect of vildagliptin on endothelium-dependent vasodilatation. A double blind, cross-over study in type 2 diabetes. - Vildagliptin and vasodilatatioThe effect of vildagliptin on endothelial dysfunction in type 2 diabetes, assessed by measuring endothelium-dependent vasodilatationMedDRA version: 12.0Level: LLTClassification code 10048554Term: Endothelial dysfunction
EUCTR2009-016053-18-NLMC St Radboud16
Recruiting
Not Applicable
Effects of vildagliptin on vascular endothelial function and lipid profile in patients with type 2 diabetes mellitus
JPRN-UMIN000008134Department of Medicine and Bioregulatory Sciences, The University of Tokuhsima, Graduate School of Health Biosciences20
Completed
Not Applicable
Effect of sitagliptin on vascular endothelial function in Type 2 diabetesType 2 diabetes
JPRN-UMIN000009948Tokyo Women&#39;s Medical University50
Completed
Not Applicable
The effect of trelagliptin on vascular endothelial functions in patients with type II diabetes mellitus.Patients with type 2 diabetes
JPRN-UMIN000018311Ise Red Cross Hospital Department of Metabolic Diseases30
Completed
Not Applicable
Effect of alogliptin on endothelial dysfunction induced by postprandial hypelipidemia
JPRN-UMIN000008296Department of Cardiovascular Medicin,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama30